focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
RNS 13/12/23
"The Company has confirmed that it has more than doubled the number of Steriwave® deployments in 2023 and is in discussions with more than 75 hospitals in the UK, Mexico, Spain, and Canada. The growing global emphasis on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine's photodisinfection technology."
Let's hope their discussions with all 75 hospitals are successful.
In terms of cash runway the RNS on 11/12/23 stated:
"The net proceeds from the Fundraising will provide further cash runway until at least mid Q2 2024. The Company continues to evaluate funding opportunities for its Phase 3 study in the US, subject to the finalisation of the trial design with the FDA, and for further commercial development internationally."
Question: will another fundraise be required?
The snowball is certainly gaining momentum as revenues will likely follow
First commercial adoption of Steriwave by the NHS
NHS deal gives patients access to groundbreaking
I have been following this for more than a year and made a first investment today of 45k shares (shown as a sell on here). I will buy more if I could understand the financial side and likely revenue from the NHS and other hospitals adopting Steriwave. Research continues.
Looks like the snowball has started to roll down hill
Well, that is a perfect answer to the question I raised yesterday about the Pontefract trial.
This is a pivotal RNS and exactly what I suspected in my last post. This really does open the door for Steriwave adoption across the NHS. YHEC is one of the prime influences within the NHS and acts as a first mover in many cases of national rollout. Excellent news that their pilot and subsequent appraisal has led to adoption. The cost savings if universally adopted across the NHS would be 'substantial' according to Ondine.
Sisyphus - thank you for your response.
As far as I can make out YHEC is undertaking an economic analysis based on results from primarily the Pontefract trial. I would expect conclusions from that are due any time. Since YHEC is an influencer for NHS policy it will look at savings that adoption of Steriwave could achieve. This could be quite a pivotal time for Ondine. Positive studies across the globe are accumulating.
I would be obliged if someone could explain the difference between the pilot at Pontefract Hospital and the YHEC evaluation.
Have the results of the Pontefract pilot been released?
1 Aug 2023 RNS
“Ondine commences first NHS Steriwave® pilot
Mid Yorkshire Teaching NHS Trust will be using Ondine's nasal photodisinfection therapy prior to orthopaedic surgeries at Pontefract Hospital over a six-month pilot”
5 Mar 2024 RNS
“Ondine starts first UK health economics study
The York Health Economic Consortium will undertake the first UK health economic analysis of Ondine's Steriwave light-activated antimicrobial to reduce Surgical Site Infections
Ondine Biomedical Inc. (LON:OBI), Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire and Humber are partnering with the York Health Economics Consortium (YHEC) to evaluate the use of Ondine's light-activated antimicrobial, Steriwave®, to reduce the incidence of surgical site infections (SSIs).”
Target 60p
How on earth is this still independent with all the info finally gaining traction in hospitals and word of mouth initiating the long awaited snowball effect?
The 2023 results should be available in May. Whilst more trials provide valuable information regarding the efficacy of the product and the potential cost savings, revenue generation is important. In 2022, there was loss before tax $19.5 million.
All the studies reported on so far show significant cost benefits, as well as better patient outcomes. I hope progress towards improving revenues has been made (2022 Revenues were $0.6 million)
I will be interested to see what progress has been made re the Phase 3 trial.
9.535-9.9p
Steriwave study shows 77% drop in antibi
This'll get bought out as its tech is gaining greater momentum.
Money safer here than Horizonte Minerals! This will be bought out once it gains a bit more traction.
Just talks about reduction in nasal surgery, which is where it is administered.
We need more trials and testing on all forms of surgeries, but it is positive news regardless
Surprised to read used in Canada for 10 years now, yet pitiful revenues to show for it
Can this make serious money from this tech?
This is a game changer.
Just my opinion
but looks likely
9.55-10.4p
The buying of big chunks continues. £175k is a lot of confidence. There is also the compelling case to bring this under the umbrella of eg Halma Stryker or S&N to grab the traction now. Interesting and huge potential. The benefits wrt Mupirocin are constantly being uprated.
Results presented at the the prestigious SPIE Photonics West conference
(https://www.londonstockexchange.com/news-article/OBI/microbiome-research-supports-use-of-steriwave/16310998)
on 30 January 2024 in San Francisco, California showed that treatment with
Ondine's Steriwave® Nasal Photodisinfection System significantly reduces
pathogens in the nose without long-term adverse effects on the nasal
microbiome. This is an important finding to allay potential concerns as to a
possible side-effect of Steriwave treatment, which has been used in over
150,000 patients with no serious adverse events reported.
5 million shares BUYS today means some thing is happening
Some stonkingly big buys arriving this afternoon.